Alnylam Pharmaceuticals
ALNY
#648
Rank
S$41.45 B
Marketcap
$321.43
Share price
-7.08%
Change (1 day)
40.14%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Alnylam Pharmaceuticals (ALNY) - Total debt

Total debt on the balance sheet as of September 2024 : S$1.74 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's total debt is S$1.74 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

Alnylam Pharmaceuticals - Total debt on balance sheet (from 2003 to 2024)

Total debt by year

Year Total debt Change
2023-12-31S$1.72 B-2.59%
2022-12-31S$1.76 B31.24%
2021-12-31S$1.34 B95.6%
2020-12-31S$0.68 B68.33%
2019-12-31S$0.40 B899.42%
2018-12-31S$40.98 M2.14%
2017-12-31S$40.12 M-81.52%
2016-12-31S$0.21 B
2007-12-31S$9.72 M-30.58%
2006-12-31S$14 M13.78%
2005-12-31S$12.31 M4.81%
2004-12-31S$11.74 M271.95%
2003-12-31S$3.15 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
S$0.15 B-90.93%๐Ÿ‡บ๐Ÿ‡ธ USA
S$3.62 B 107.71%๐Ÿ‡บ๐Ÿ‡ธ USA
S$1.87 B 7.35%๐Ÿ‡บ๐Ÿ‡ธ USA
S$0.36 B-79.30%๐Ÿ‡บ๐Ÿ‡ธ USA
S$0.9 M-99.95%๐Ÿ‡บ๐Ÿ‡ธ USA
S$43.13 B 2,370.29%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
S$34.14 B 1,855.76%๐Ÿ‡ซ๐Ÿ‡ท France
S$25.85 B 1,380.61%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel